- Home
- Publications
- Publication Search
- Publication Details
Title
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-21
DOI
10.1038/s41598-018-32659-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The LIN28/let-7 Pathway in Cancer
- (2017) Julien Balzeau et al. Frontiers in Genetics
- Advances in Risk Classification and Treatment Strategies for Neuroblastoma
- (2015) Navin R. Pinto et al. JOURNAL OF CLINICAL ONCOLOGY
- Neuroblastoma
- (2015) Meredith S. Irwin et al. PEDIATRIC CLINICS OF NORTH AMERICA
- A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
- (2015) Giselle L. Saulnier Sholler et al. PLoS One
- Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma
- (2015) Ann M. Lozier et al. Oncotarget
- Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems
- (2014) L E Cohen et al. BONE MARROW TRANSPLANTATION
- Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
- (2014) Brian H. Kushner et al. CLINICAL CANCER RESEARCH
- AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport
- (2013) Katherine Samal et al. INTERNATIONAL JOURNAL OF CANCER
- DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma
- (2013) DANA-LYNN T. KOOMOA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
- (2012) Nai-Kong V. Cheung et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of -Difluoromethylornithine in Subjects with Previous History of Skin Cancer
- (2010) H. H. Bailey et al. Cancer Prevention Research
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
- (2009) R. J. Rounbehler et al. CANCER RESEARCH
- Associations of a Polymorphism in the Ornithine Decarboxylase Gene with Colorectal Cancer Survival
- (2009) J. A. Zell et al. CLINICAL CANCER RESEARCH
- Genetic polymorphism in ornithine decarboxylase and risk of breast cancer
- (2009) Iain Brown et al. Familial Cancer
- New therapeutic targets for the treatment of high-risk neuroblastoma
- (2009) Lars M. Wagner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
- (2009) Caroline Laverdière et al. JNCI-Journal of the National Cancer Institute
- Disease control intervals in high-risk neuroblastoma
- (2008) Victor M. Santana et al. CANCER
- Ornithine Decarboxylase Inhibition by -Difluoromethylornithine Activates Opposing Signaling Pathways via Phosphorylation of Both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma
- (2008) D.-L. T. Koomoa et al. CANCER RESEARCH
- ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
- (2008) M. D. Hogarty et al. CANCER RESEARCH
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
- (2008) Susan L. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now